Latest MS news, study updates, product approvals, and more.

By Laura Kolaczkowski - February 21, 2016
It was announced February 17, 2016, that the drug, ocrelizumab made by Roche and Genentech pharmaceutical companies, has been given Breakthrough Therapy Designation for the treatment of primary progressive MS by the... READ MORE

By Laura Kolaczkowski - October 11, 2015
People with primary progressive multiple sclerosis (PPMS) finally have something to cheer about in a potential disease modifying therapy. Genentech and Roche pharmaceutical companies announced the results of their studies of ocrelizumab in... READ MORE

By Lisa Emrich - July 20, 2015
A second case of progressive multifocal leukoencephalopathy (PML) has been reported in an MS patient taking Tecfidera (delayed-release dimethyl fumarate), an oral disease-modifying therapy approved to treat relapsing forms of multiple sclerosis.... READ MORE

By Editorial Team - April 17, 2015
On April 16, Novartis announced the Food & Drug Administration (FDA) approval of Glatopa, the first generic alternate for Teva’s widely used multiple sclerosis therapy, Copaxone. The once per day therapy was developed in collaboration between... READ MORE

SubscribeJoin 45,000 subscribers to our weekly newsletter.

Your username will be visible to others.

Reader favorites